CONTINUING MEDICAL EDUCATION
The University of Texas Health Science Center at San Antonio Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Joe R. and Teresa Lozano Long School of Medicine designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The American Academy of Physician Assistants (AAPA), American Academy of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC) accepts certificates of attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Healthcare professionals receiving a certificate of attendance should consult with their licensing board for information on applicability and acceptance.
These regional symposia are directed to academic and community physicians, medical residents and fellows training in oncology subspecialties, physician assistants, nurse practitioners and basic/translational researchers involved in breast cancer. Specialties include medical, surgical, gynecologic, and radiation oncology, as well as other pertinent healthcare professionals involved in breast cancer medicine.
I. IDENTIFY factors that predispose individuals and increase the risk of developing breast cancer.
II. LIST prognostic and predictive molecular signatures and biomarkers that can identify the most appropriate treatment strategies for individuals with breast cancer.
III. DISCUSS scientific advances from the laboratory that have great potential to translate into increased knowledge of breast cancer biology and pathogenesis.
IV. REVIEW new results from clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium.
V. ELABORATE on results of evidence from preclinical research and clinical trials that support the rational combinations of traditional and newer pharmacologic interventions, with a focus on novel therapeutics and resistance mechanisms.
VI. DEVELOP appropriate individualized treatment strategies for those patients who would benefit from new treatments in all the major subtypes of breast cancer and also focus on reversing resistance to commonly used therapies.
Education to improve physician understanding of the latest trial data, guidelines, and applications in clinical practice has been identified as a vehicle for closing the knowledge gap and helping to improve patient outcomes [Christian 2006]. This proposed CME symposium will address the above gaps in clinical practice/knowledge between what is known and what healthcare practitioners wish to better understand regarding the screening, diagnosis, and management of patient with BC. In addition, it will focus on identified research/presentations from SABCS 2017 that cover these issues, including results of BC research, facilitating the rapid translation of new knowledge into better care for breast cancer patients and addressing issues such as axillary management in primary BC, human epidermal growth factor receptor 2 (HER2), cell cycle regulation with CDK inhibitors, genomic heterogeneity, and proteomic analysis of BC.
Best of SABCS Meetings are supported by educational grants from Lilly, Novartis, AstraZeneca, AGENDIA, Puma Biotechnology Inc., Eisai, Biotheranostics, Inc., and Genomic Health.
The Westin New York Grand Central, 212 E 42nd St, New York, NY 10017.